Helicobacter pylori and gastroesophageal reflux disease

Current Treatment Options in Gastroenterology

Volumn 7, Issue 1, 2004, Pages 59-70

  Peek Jr , Richard M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ASTEMIZOLE; BISMUTH SALICYLATE; CHINESE DRUG; CISAPRIDE; CLARITHROMYCIN; ESOMEPRAZOLE; FURAZOLIDONE; HELIDAC; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; MONOAMINE OXIDASE INHIBITOR; OMEPRAZOLE; PANTOPRAZOLE; PIMOZIDE; PREVPAC; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TERFENADINE; TETRACYCLINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALOPECIA; ANGIONEUROTIC EDEMA; ANXIETY; ARTHRALGIA; ASTHENIA; ATROPHIC GASTRITIS; BACKACHE; BACTERIAL COLONIZATION; BARRETT ESOPHAGUS; BODY WEIGHT DISORDER; BRAIN DISEASE; BRAIN PSEUDOTUMOR; BRONCHITIS; BRONCHOSPASM; BULLOUS SKIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONVULSION; COUGHING; CYSTITIS; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ALCOHOL INTERACTION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSPEPSIA; DYSPNEA; DYSURIA; ERADICATION THERAPY; ESOPHAGITIS; ESOPHAGUS CARCINOMA; ESOPHAGUS ULCER; FANCONI RENOTUBULAR SYNDROME; FLATULENCE; FLU LIKE SYNDROME; FLUSHING; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GLOSSITIS; HEADACHE; HEART ARRHYTHMIA; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMATOLOGIC DISEASE; HEMOLYSIS; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INFECTION; INSOMNIA; LEUKOCYTOSIS; LIVER TOXICITY; LONG TERM CARE; MALAISE; MYALGIA; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; NEUTROPENIA; NON INVASIVE MEASUREMENT; NONHUMAN; PANCREATITIS; PARESTHESIA; PEPTIC ULCER; PERIPHERAL EDEMA; PHARYNGITIS; PHOTOSENSITIVITY; PRURITUS; PSEUDOMEMBRANOUS COLITIS; REFLUX ESOPHAGITIS; REVIEW; RHINITIS; RISK FACTOR; SINUSITIS; SMELLING DISORDER; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; STOMACH CANCER; STOMACH FUNDOPLICATION; STOMACH MUCOSA; STOMATITIS; SWEATING; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; URINARY DYSFUNCTION; URINARY FREQUENCY; URINE RETENTION; URTICARIA; UVEITIS; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 3142732139     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0026-0     Document Type: Review

References (46)

1. Everhart JE: Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000, 29:559-578.
2. Ernst PB, Gold BD: The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000, 54:615-640.
3. Peek RM Jr, Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002, 2:28-37.
4. Parsonnet J: The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9:45-51.
5. Howson CP, Hiyama T, Wynder EL: The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev 1986, 8:1-27.
6. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
7. Werdmuller BF, Loffeld RJ: Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997, 42:103-105.
8. Varanasi RV, Fantry GT, Wilson KT: Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease. Helicobacter 1998, 3:188-194.
9. Weston AP, Badr AS, Topalovski M, et al.: Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000, 95:387-394.
10. Haruma K, Hamada H, Mihara M, et al.: Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan. Helicobacter 2000, 5:24-29.
11. Vicari JJ, Peek RM, Falk GW, et al.: The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998, 115:50-57.
12. Chow WH, Blaser MJ, Blot WJ, et al.: An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998, 58:588-590.
13. Loffeld RJ, Werdmuller BF, Kuster JC, et al.: Colonization with cagA-positive Helicobacter pylori strains is inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000, 62:95-99.
14. Warburton-Timms VJ, Charlett A, Valori RM, et al.: The significance of cagA(+) Helicobacter pylori in reflux oesophagitis. Gut 2001, 49:341-346.
15. Raghunath A, Hungin AP, Wooff D, et al.: Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003, 326:737-743.
16. Sharma P, Vakil N: Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003, 17:297-305.
17. El-Serag HB, Sonnenberg A, Jamal MM, et al.: Corpus gastritis is protective against reflux oesophagitis. Gut 1999, 45:181-185.
18. Koike T, Ohara S, Sekine H, et al.: Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001, 49:330-334.
19. Labenz J, Blum AL, Bayerdorffer E, et al.: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997, 112:1442-1447.
20. Sasaki A, Haruma K, Manabe N, et al.: Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2003, 17:1529-1534.
21. Schwizer W, Thumshirn M, Dent J, et al.: Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001, 357:1738-1742.
22. Moayyedi P, Bardhan C, Young L, et al.: Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001, 121:1120-1126.
23. Tefera S, Hatlebakk JG, Berstad A: The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999, 13:915-920.
24. Porro GB, Pace F: Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease? Eur J Gastroenterol Hepatol 2000, 12:S7-S10.
25. Kuipers EJ, Uyterlinde AM, Pena AS, et al.: Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995, 90:1401-1406.
26. Falk GW: The possible role of Helicobacter pylori in GERD. Semin Gastrointest Dis 2001, 12:186-195.
27. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996, 334:1018-1022.
28. Correa P: Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996, 5:477-481.
29. Eissele R, Brunner G, Simon B, et al.: Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997, 112:707-717.
30. Klinkenberg-Knol EC, Nelis F, Dent J, et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000, 118:661-669.
31. Stolte M, Meining A, Schmitz JM, et al.: Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998, 12:247-253.
32. Lundell L, Miettinen P, Myrvold HE, et al.: Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999, 117:319-326.
33. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al.: Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999, 94:884-887.
34. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al.: Helicobacter pylori eradication for the prevention of atrophic gastritis during omeprazole therapy: a prospective randomized trial. Gastroenterology 2001, 120:A14.
35. Labenz J, Tillenburg B, Peitz U, et al.: Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996, 110:725-732.
36. Miehlke S, Bayerdorffer E, Graham DY: Treatment of Helicobacter pylori infection. Semin Gastrointest Dis 2001, 12:167-179.
37. Malfertheiner P, Megraud F, O'Morain C, et al.: Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002, 16:167-180.
38. Ulmer HJ, Beckerling A, Gatz G: Recent use of proton pump inhibitor-based triple therapies for the eradication of Helicobacter pylori: a broad data review. Helicobacter 2003, 8:95-104.
39. Vaira D, Holton J, Ricci C, et al.: Review article: Helicobacter pylori infection from pathogenesis to treatment - a critical reappraisal. Aliment Pharmacol Ther 2002, 16:105-113.
40. Basset C, Holton J, Ricci C, et al.: Diagnosis and treatment of Helicobacter: a 2002 updated review. Aliment Pharmacol Ther 2003, 17:89-97.
41. Bazzoli F, Zagari RM, Pozzato P, et al.: Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2002, 16:153-158.
42. Choi IJ, Jung HC, Choi KW, et al.: Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002, 16:145-151.
43. Vallve M, Vergara M, Gisbert JP, et al.: Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther 2002, 16:1149-1156.
44. Qasim A, O'Morain CA: Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002, 16:24-30.
45. Givens RC, Watkins PB: Pharmacogenetics and clinical gastroenterology. Gastroenterology 2003, 125:240-248.
46. Macfarlane GT, Cummings JH: Probiotics, infection and immunity. Curr Opin Infect Dis 2002, 15:501-506.